Navigation Links
Dynatronics Announces First Quarter Results
Date:11/14/2012

SALT LAKE CITY, Nov. 14, 2012 /PRNewswire/ -- Dynatronics Corporation (NASDAQ: DYNT) today announced results for its fiscal first quarter ended September 30, 2012.

Net loss for the quarter ended June 30, 2012, improved to $51,145 ($.00 per common share), compared to net loss of $68,259 ($.01 per common share) for the same quarter in the prior fiscal year. Sales for the fiscal first quarter ended September 30, 2012, declined 9.9 percent to $7,206,025, compared to $7,996,802 for the quarter ended September 30, 2011.

"A backlog of orders for our new SolarisPlus product line and other products dampened first quarter results," said Kelvyn H. Cullimore Jr., chairman and president of Dynatronics. "This was compounded by reduced sales of capital exercise products, motorized treatment tables and certain other products, together with continued weakness in the economy.

"On a positive note," Cullimore continued, "during the reporting quarter, we were successful in reducing SG&A and R&D costs by approximately $325,800. This allowed us to reduce the first quarter loss compared to last year despite the weakness in sales."

Company management has developed a strategic plan to build on the popularity of the new SolarisPlus product line and overcome the current challenging economic trends. This plan calls for (1) an expansion of Dynatronics' distribution channels to penetrate a broader segment of the market, and (2) the introduction of a record number of new products this fiscal year to boost interest in the company's most profitable capital equipment products.

"The new products that are currently under development will allow us to expand distribution and help us capture greater market share in the physical medicine market," Cullimore added. "The development of the new products is made possible by the technology platform we built over the past two years of intense R&D effort. As a result, the new products can be developed quickly and with minimal additional R&D expenditures."

In a separate matter, Dynatronics announced the approval of its new GSA contract with the United States government. "This contract allows us to sell therapy equipment and medical supplies to the United States government, including its Veterans Affairs medical facilities and armed forces," reported Larry K. Beardall, executive vice president of sales and marketing. "Initial orders from governmental facilities have been encouraging and we believe this segment of our business will flourish."

"Our strategy of introducing new products, combined with our distribution channel expansion and continued effort to scale costs and overhead to current sales levels, is designed to enable Dynatronics to grow and improve its financial performance," Cullimore concluded.

Dynatronics has scheduled a conference call for investors on Wednesday, November 14, 2012, at 4:30 p.m. ET. Those wishing to participate should call (800) 658-7107.

The following is a summary of the financial results as of September 30, 2012 and 2011, and for the three-month period then ended:Summary Selected Financial DataStatement of Operations HighlightsThree Months EndedSeptember 30,20122011Net sales

$ 7,206,025

$ 7,996,802Cost of sales

4,495,177

4,994,704Gross profit

2,710,848

3,002,098SG&A expenses

2,459,104

2,694,867R&D expenses

266,268

356,347Other expenses, net

59,085

56,812Net loss before income tax benefit

(73,609)

(105,928)Income tax benefit

22,464

37,669Net loss

$
(51,145)

$
(68,259)
Diluted net loss per common share

$
(0.00)

$
(0.01)
 Balance Sheet Highlights September 30,June 30,20122012Cash

$ 285,639

$ 278,263Accounts receivable

3,704,913

3,667,086Inventories

6,090,591

6,098,597Total current assets

10,714,797

10,654,158Total assets

15,238,039

15,270,930Accounts payable

2,351,542

2,413,201Accrued expenses

249,818

386,229Line of credit

3,673,334

3,497,597Total current liabilities

7,183,712

7,088,300Total liabilities

8,998,057

9,004,615Total liabilities and equity

15,238,039

15,270,930 

Dynatronics manufactures, markets and distributes advanced-technology medical devices, orthopedic soft goods and supplies, treatment tables and rehabilitation equipment for the physical therapy, sports medicine, chiropractic, podiatry, plastic surgery, dermatology and other related medical, cosmetic and aesthetic markets. More information regarding Dynatronics is available at www.dynatronics.com.

This press release contains forward-looking statements. Those statements include references to the company's expectations and similar statements such as the statement regarding expectations for future new product line introductions and growth. Actual results may vary from the views expressed in the forward-looking statements contained in this release. The development and sale of the company's products are subject to a number of risks and uncertainties, including, but not limited to, changes in the regulatory environment, competitive factors, inventory risks due to shifts in market demand, market demand for the company's products, availability of financing at cost-effective rates, and the risk factors listed from time to time in the company's SEC reports.


'/>"/>
SOURCE Dynatronics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Dynatronics To Release Fiscal Third Quarter Results Tuesday, May 15, 2012; Conference Call set for 3:30 p.m. ET
2. Dynatronics Introduces New SolarisPlus Line of Therapy Products
3. Dynatronics Will Request Hearing with Nasdaq Regarding Listing Status
4. Dynatronics To Release Fiscal First Quarter Results Wednesday, November 14, 2012; Conference Call set for 4:30 p.m. ET
5. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
6. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
7. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
8. Misonix Announces New Distribution Agreement For Panama
9. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
10. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
11. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb. 23, 2017  Cogentix Medical, Inc. ... and markets innovative proprietary products for the urology market, ... fiscal year ended December 31, 2016 before the market ... The Company will host a conference call and webcast ... Thursday, March 9, 2017 at 11:00 a.m. Eastern Time ...
(Date:2/23/2017)... Feb 23, 2017 Research and Markets has announced ... 2016" report to their offering. ... The latest research Menopause Drugs Price Analysis and Strategies - ... The research answers the following questions: ... How are they positioned in the Global Menopause market? ...
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... - 2016" report to their offering. ... The latest research Fibromyalgia Drugs Price ... in the global Fibromyalgia market. The research answers the ... marketed for Fibromyalgia and their clinical attributes? How are they positioned ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... ... , media relations, content marketing, social media management, corporate communications, SEO and cause ... the state and in nearby New Hampshire, Massachusetts and Canada, Rosica will focus ...
(Date:2/23/2017)... Colorado (PRWEB) , ... February 23, 2017 , ... ... Magazine, an exciting, new, interactive publication where generations converge and explore the world ... expand their worldview, Dialog Magazine enables readers to gain understanding, increase empathy, and ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... new partnership with the Rhode Island Consortium for Autism Research and Treatment (RI-CART) ... for children with autism spectrum disorder (ASD) to see films in an environment ...
(Date:2/23/2017)... ... 2017 , ... Curemark, LLC announced today that the Blüm Study, a Phase ... 3-8 with Autism, is now enrolling at three new sites. These new sites are ... , “There are currently no approved drugs that address the core symptoms of ...
(Date:2/22/2017)... York (PRWEB) , ... February 22, 2017 , ... ... entrance and lobby of a new healthcare contact center in Georgia, PENETRON Specialty ... One of the nation’s largest healthcare systems recently invested $51 million to purchase ...
Breaking Medicine News(10 mins):